Enzo Biochem at Bio-Europe 2009 (NYSE:ENZ)

Speaking at the Bio-Europe 2009 Conference in Austria, Enzo Biochem, Inc (NYSE:ENZ) announced that the Company’s therapeutic platforms are utilizing oral immune regulation for immune mediated diseases. The Company further said that the oral immune regulation platform is a bright area of therapeutic promise. Currently, the Company’s therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicine for uveitis and Crohn’s disease and is conducting pre-clinical research on several candidate compounds that are aimed at producing new mineral and organic bone, including therapies for osteoporosis and fractures and other applications.

The Company announced that their therapeutics subsidiary has long viewed oral immune regulation as a promising platform and that they continue to pursue this platform through studies that involve treatment candidates of unmet medical needs. Enzo Biochem’s Vice President for Corporate Development, David Goldberg, mentioned that as they are growing their Life Sciences and Clinical Labs division they are also utlizing the experience and knowledge gained in drug discovery programs to better the position of Enzo Biochem in the rapidly growing companion diagnostics space. He further stated that the Company has made progress in the development of its drug screening platform that has yielded orally delivered small molecules having potential effects for bone disorders and diabetes.

Enzo Biochem looks after the research and development, manufacturing and licensing of innovative healthcare products and technologies based on molecular biology and genetic engineering and in providing diagnostic services to the medical community. The Company currently has two ongoing clinical studies. Alequal is an individualized therapy for the treatment of Crohn’s disease and is a Phase 2 clinical trial with no treatment side effects. Optiquel is an oral novel peptide designed to inhibit progression of autoimmune aveitis.